🦠 Combined Pap Smear and HPV Vaccination Strategy Simulator

No Prevention — Full HPV and Cancer Risk

No vaccine, no screening — infection and progression proceed unchecked.

• 80%: HPV lifetime exposure (of sexually active adults)
• 14: High-risk HPV types (linked to cervical cancer)
• 10–20 yrs: Progression window (infection to invasive cancer)
• 350k: Annual global deaths (cervical cancer mortality)

Unblocked infection

HPV enters cervical cells freely with no immune priming.

Silent progression

Dysplasia advances undetected with no screening safety net.

Late-stage discovery

Cancer is often found only after symptoms appear.

Vaccination Only — Infection Blocked, No Safety Net

Vaccine blocks covered strains, but the screening gap stays open.

• ~90%: Vaccine efficacy (against covered HPV strains)
• 9: Strains covered (nonavalent vaccine)
• 0%: Screening active (no cytology performed)
• uncovered types: Breakthrough exposure (still fully unprotected)

Outer shield active

Antibodies neutralize HPV before cervical cell entry.

Coverage gap

Non-vaccine strains can still infect and progress silently.

No detection layer

Any breakthrough disease goes uncaught without screening.

Screening Only — Unvaccinated but Monitored

No vaccine, but Pap cytology catches dysplasia before cancer forms.

• ~75%: Pap sensitivity (per single screening round)
• 0%: Infection prevention (no vaccine layer present)
• adherence: Detection driver (attendance sets capability)
• CIN2/3: Treatable precancer stage (caught before invasion)

No outer shield

HPV infects freely with no vaccine block in place.

Inner shield engaged

Cytology screens catch abnormal cervical cells.

Adherence dependent

Detection power scales directly with screening attendance.

Vaccination Plus Screening — Two Independent Layers

Infection is blocked and any residual disease is caught early.

• ~98%: Combined protection (two independent layers multiplied)
• ~90%: Infection prevention (vaccine layer)
• adherence-scaled: Early detection (screening layer)
• <5%: Residual risk (rare breakthrough cases only)

Outer shield first

Vaccination stops most infections before they start.

Inner shield backup

Screening catches whatever breakthrough infection remains.

Independent layers multiply

Combined protection exceeds either layer used alone.

Maximal Protection — Full Two-Layer Coverage

High vaccination and full screening adherence minimize cancer risk.

• ~99%: Combined protection (at full adherence)
• ~1–2%: Residual cancer risk (irreducible minimum)
• millions: Lives saved potential (with global scale-up)
• 90-70-90: WHO elimination target (vaccination-screening-treatment goals)

Full outer coverage

Nearly all vaccine-preventable infections are stopped outright.

Full inner coverage

Consistent screening catches nearly all residual disease early.

Near-elimination state

Together the layers approach cervical cancer elimination targets.